UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2015
PACIRA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35060 |
|
51-0619477 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
5 Sylvan Way, Suite 300, Parsippany, New Jersey 07054
(Address of principal executive offices) (Zip Code)
(973) 254-3560
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 2, 2015, Pacira Pharmaceuticals, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders at the Company’s corporate headquarters in Parsippany, New Jersey, at which the Company’s stockholders voted on, and approved, the following proposals:
Proposal No. 1 — Election of three Class I directors to hold office until the 2018 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.
|
Nominee: |
|
For |
|
Withheld |
|
Broker Non- |
|
|
Laura Brege |
|
25,148,577 |
|
2,703,160 |
|
5,270,606 |
|
|
Mark A. Kronenfeld |
|
26,686,306 |
|
1,165,431 |
|
5,270,606 |
|
|
Dennis L. Winger |
|
27,763,019 |
|
88,718 |
|
5,270,606 |
|
Proposal No. 2 — Ratification of the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.
|
For |
|
Against |
|
Abstain |
|
|
33,054,850 |
|
41,601 |
|
25,892 |
|
Proposal No. 3 — Advisory vote to approve the compensation of the Company’s named executive officers.
|
For |
|
Against |
|
Abstain |
|
Broker Non- |
|
|
27,579,771 |
|
214,828 |
|
57,138 |
|
5,270,606 |
|
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PACIRA PHARMACEUTICALS, INC. | |
|
|
| |
|
Date: June 3, 2015 |
By: |
/s/ James Scibetta |
|
|
|
James Scibetta |